Clinical trial
A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
NCT00397384 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical and Biological Evaluation of Combined EGFR Blockade With Erlotinib and Cetuximab in Patients With Advanced Cancer
- Lead sponsor
- National Cancer Institute (NCI)
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2007
- Completion date
- June 30, 2013
- Enrollment
- 43 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma of the colon, adenocarcinoma of the rectum, advanced adult primary liver cancer, carcinoma of the appendix, gastrointestinal stromal tumor, metastatic gastrointestinal carcinoid tumor, metastatic squamous neck cancer with occult primary, recurrent adenoid cystic carcinoma of the oral cavity, recurrent adult primary liver cancer, recurrent anal cancer, recurrent basal cell carcinoma of the lip, recurrent colon cancer, recurrent esophageal cancer, recurrent esthesioneuroblastoma of the paranasal sinus and nasal cavity, recurrent extrahepatic bile duct cancer, recurrent gallbladder cancer, recurrent gastric cancer, recurrent gastrointestinal carcinoid tumor, recurrent inverted papilloma of the paranasal sinus and nasal cavity, recurrent lymphoepithelioma of the nasopharynx, recurrent lymphoepithelioma of the oropharynx, recurrent metastatic squamous neck cancer with occult primary, recurrent midline lethal granuloma of the paranasal sinus and nasal cavity, recurrent mucoepidermoid carcinoma of the oral cavity, recurrent non-small cell lung cancer, recurrent pancreatic cancer, recurrent rectal cancer, recurrent salivary gland cancer, recurrent small intestine cancer, recurrent squamous cell carcinoma of the hypopharynx, recurrent squamous cell carcinoma of the larynx, recurrent squamous cell carcinoma of the lip and oral cavity, recurrent squamous cell carcinoma of the nasopharynx, recurrent squamous cell carcinoma of the oropharynx, recurrent squamous cell carcinoma of the paranasal sinus and nasal cavity, recurrent verrucous carcinoma of the larynx, recurrent verrucous carcinoma of the oral cavity, small intestine adenocarcinoma, small intestine leiomyosarcoma, small intestine lymphoma, stage iv adenoid cystic carcinoma of the oral cavity, stage iv anal cancer, stage iv basal cell carcinoma of the lip, stage iv colon cancer, stage iv esophageal cancer, stage iv esthesioneuroblastoma of the paranasal sinus and nasal cavity, stage iv gastric cancer, stage iv inverted papilloma of the paranasal sinus and nasal cavity, stage iv lymphoepithelioma of the nasopharynx, stage iv lymphoepithelioma of the oropharynx, stage iv midline lethal granuloma of the paranasal sinus and nasal cavity, stage iv mucoepidermoid carcinoma of the oral cavity, stage iv non-small cell lung cancer, stage iv pancreatic cancer, stage iv rectal cancer, stage iv salivary gland cancer, stage iv squamous cell carcinoma of the hypopharynx, stage iv squamous cell carcinoma of the larynx, stage iv squamous cell carcinoma of the lip and oral cavity, stage iv squamous cell carcinoma of the nasopharynx, stage iv squamous cell carcinoma of the oropharynx, stage iv squamous cell carcinoma of the paranasal sinus and nasal cavity, stage iv verrucous carcinoma of the larynx, stage iv verrucous carcinoma of the oral cavity, tongue cancer, unresectable extrahepatic bile duct cancer, unresectable gallbladder cancer